Literature DB >> 34741329

Editorial: risk of pneumonia in IBD-reading between the lines!

Joseph Meserve1, Siddharth Singh1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34741329      PMCID： PMC8601591          DOI： 10.1111/apt.16655

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  9 in total

Review 1.  Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases.

Authors:  Ariela Holmer; Siddharth Singh
Journal:  Expert Rev Clin Immunol       Date:  2019-07-25       Impact factor: 4.473

2.  Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.

Authors:  Siddharth Singh; Antonio Facciorusso; Parambir S Dulai; Vipul Jairath; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2019-03-12       Impact factor: 11.382

Review 3.  Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease.

Authors:  Daniele Piovani; Silvio Danese; Laurent Peyrin-Biroulet; Georgios K Nikolopoulos; Stefanos Bonovas
Journal:  Aliment Pharmacol Ther       Date:  2020-03-13       Impact factor: 8.171

4.  The Association of Medications and Vaccination with Risk of Pneumonia in Inflammatory Bowel Disease.

Authors:  Martin H Gregory; Matthew A Ciorba; Wyndy L Wiitala; Ryan W Stidham; Peter Higgins; S Celeste Morley; Jason K Hou; Linda A Feagins; Shail M Govani; Shirley A Cohen-Mekelburg; Akbar K Waljee
Journal:  Inflamm Bowel Dis       Date:  2020-05-12       Impact factor: 5.325

5.  Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.

Authors:  Siddharth Singh; Herbert C Heien; Jeph Herrin; Parambir S Dulai; Lindsey Sangaralingham; Nilay D Shah; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2021-02-25       Impact factor: 11.382

6.  Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.

Authors:  Gary R Lichtenstein; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Robert H Diamond; Samiyeh Price; Wayne Langholff; Anil Londhe; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2012-08-14       Impact factor: 10.864

7.  AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease.

Authors:  Joseph D Feuerstein; Edith Y Ho; Eugenia Shmidt; Harminder Singh; Yngve Falck-Ytter; Shanaz Sultan; Jonathan P Terdiman
Journal:  Gastroenterology       Date:  2021-06       Impact factor: 33.883

Review 8.  AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease.

Authors:  Siddharth Singh; Deborah Proctor; Frank I Scott; Yngve Falck-Ytter; Joseph D Feuerstein
Journal:  Gastroenterology       Date:  2021-06       Impact factor: 33.883

9.  Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease.

Authors:  Julien Kirchgesner; Rishi J Desai; Laurent Beaugerie; Sebastian Schneeweiss; Seoyoung C Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2020-12-30       Impact factor: 11.382
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.